Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Neuronal protein could be a promising anti-cancer target

By lowering the level of a neuronal protein, researchers halted the growth of blood vessels that tumors rely on for survival. The findings are reported online in the Journal of Experimental Medicine (www.jem.org) on Jan. 4.

5 Jan 2010

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

Self-seeding process of cancer cells can enhance tumor growth, says study

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs.

27 Dec 2009

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study.

23 Dec 2009

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.

22 Dec 2009

Bioheart makes breakthrough in stem cell treatment for critical limb ischemia

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis or the formation of new blood vessels and providing support for the healing of damaged blood vessels.

22 Dec 2009

Researchers follow steps that lead some tumor cells to establish metastases

Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious.

21 Dec 2009

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Today, the Ben and Catherine Ivy Foundation (Ivy Foundation), announced that it is funding roughly $10 million for four new patient-focused research projects. As with all Ivy Foundation awards, these projects focus on improving the survival and quality of life for people with brain tumors but also specifically address new strategies to improve treatment development.

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $4.4 million.

10 Dec 2009

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.

9 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Long-chain omega-3 fatty acids can prevent colorectal cancer

Long-chain omega-3 fatty acids, primarily found in fish and seafood, may have a role in colorectal cancer prevention, according to results presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9, 2009, in Houston.

8 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

Angiogenesis News and Research

Further Reading

Neuronal protein could be a promising anti-cancer target

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Self-seeding process of cancer cells can enhance tumor growth, says study

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Bioheart makes breakthrough in stem cell treatment for critical limb ischemia

Researchers follow steps that lead some tumor cells to establish metastases

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Discovery may yield new treatments for hormone-resistant prostate cancer

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Long-chain omega-3 fatty acids can prevent colorectal cancer

SU2C awards $9.68 million to support high-risk cancer research

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo